- Home
- SRRK
as of 12-05-2025 3:45pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.6B | IPO Year: | 2018 |
| Target Price: | $47.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.71 - $46.98 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 20271.77% |
AI-Powered SRRK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
Director
Avg Cost/Share
$38.70
Shares
113,025
Total Value
$4,368,808.26
Owned After
405,828
Director
Avg Cost/Share
$36.59
Shares
387,414
Total Value
$14,438,543.93
Owned After
405,828
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$30.67
Shares
3,353
Total Value
$102,846.23
Owned After
108,964
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$33.52
Shares
3,178
Total Value
$106,526.56
Owned After
108,964
SEC Form 4
Director
Avg Cost/Share
$32.84
Shares
1,006
Total Value
$32,725.69
Owned After
33,914
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | SRRK | Director | Oct 6, 2025 | Buy | $38.70 | 113,025 | $4,368,808.26 | 405,828 | |
| AKKARAJU SRINIVAS | SRRK | Director | Oct 3, 2025 | Buy | $36.59 | 387,414 | $14,438,543.93 | 405,828 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 22, 2025 | Sell | $30.67 | 3,353 | $102,846.23 | 108,964 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 16, 2025 | Sell | $33.52 | 3,178 | $106,526.56 | 108,964 | |
| Peng Katie | SRRK | Director | Sep 16, 2025 | Sell | $32.84 | 1,006 | $32,725.69 | 33,914 |
Compare SRRK vs Leading Stocks
See how SRRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.